Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oragenics ( (OGEN) ) has shared an update.
On December 11, 2025, Oragenics, Inc. announced adjustments to its executive compensation plan. The Board of Directors approved a 5% salary increase for CEO Janet Huffman, effective January 1, 2026, raising her annual base salary to $341,250. Additionally, she received a bonus of $110,500 based on her performance. The Board also granted her options to purchase 250,000 shares of company stock, with vesting over three years. Non-Employee Directors received options for 125,000 shares, which vested immediately. Natasha Giordano, appointed to the Board on September 1, 2025, was awarded an onboarding stock option valued at $30,000, which vested immediately.
Spark’s Take on OGEN Stock
According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.
Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.
To see Spark’s full report on OGEN stock, click here.
More about Oragenics
Average Trading Volume: 127,681
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.81M
Learn more about OGEN stock on TipRanks’ Stock Analysis page.